News & Updates
Filter by Specialty:

Real-world data favour tirzepatide over semaglutide for weight loss
Tirzepatide appears to yield substantially greater reductions in weight than semaglutide in the real-world treatment of overweight or obesity in adults with or without diabetes, according to a study.
Real-world data favour tirzepatide over semaglutide for weight loss
25 Jul 2024
Poor glycaemic control ups kidney function decline after DKD onset
Poor glycaemic control in patients with type 1 (T1D) or type 2 diabetes (T2D) contributes to a faster estimated glomerular filtration rate (eGFR) decline following diabetic kidney disease (DKD) onset, suggests a study. This association is more pronounced among those with severe albuminuria.
Poor glycaemic control ups kidney function decline after DKD onset
22 Jul 2024
Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.